Brentuximab vedotin use in pediatric anaplastic large cell lymphoma.
ALCL
Brentuximab vedotin
CD30
anaplastic large cell lymphoma
non-Hodgkin lymphoma
pediatric
Journal
Frontiers in immunology
ISSN: 1664-3224
Titre abrégé: Front Immunol
Pays: Switzerland
ID NLM: 101560960
Informations de publication
Date de publication:
2023
2023
Historique:
received:
10
04
2023
accepted:
10
05
2023
medline:
7
6
2023
pubmed:
5
6
2023
entrez:
5
6
2023
Statut:
epublish
Résumé
Anaplastic large cell lymphoma (ALCL) is the most common type of mature T-cell non-Hodgkin lymphoma in children/adolescents. ALCL is characterized by expression of CD30 in the neoplastic lymphoid cells with frequent expression of anaplastic lymphoma kinase (ALK), especially within the pediatric population. Despite multiple efforts to optimize the use of conventional chemotherapy, outcomes in children, adolescents, and adults with ALCL remain suboptimal. Thus, there is a need to improve survival for those with high-risk disease and decrease therapy exposures and toxicities for those with low-risk disease. Targeted therapies, such as the anti-CD30 antibody-drug conjugate, brentuximab vedotin, are new important therapeutic options. Phase I and II studies in adults with relapsed/refractory CD30
Identifiants
pubmed: 37275877
doi: 10.3389/fimmu.2023.1203471
pmc: PMC10232850
doi:
Substances chimiques
Brentuximab Vedotin
7XL5ISS668
Antineoplastic Agents
0
Immunoconjugates
0
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
1203471Informations de copyright
Copyright © 2023 Agrusa, Egress and Lowe.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
Proc Natl Acad Sci U S A. 2008 Dec 30;105(52):20852-7
pubmed: 19088198
J Clin Invest. 2017 Sep 1;127(9):3462-3471
pubmed: 28805662
N Engl J Med. 2010 Nov 4;363(19):1812-21
pubmed: 21047225
J Clin Oncol. 2012 Jun 20;30(18):2190-6
pubmed: 22614995
Am J Hematol. 2015 Sep;90(9):790-5
pubmed: 26096944
Blood. 1994 Sep 1;84(5):1361-92
pubmed: 8068936
J Clin Pathol. 1997 Feb;50(2):128-34
pubmed: 9155693
Blood. 2000 Dec 1;96(12):3681-95
pubmed: 11090048
Blood. 2010 Nov 4;116(18):3418-25
pubmed: 20660290
Cancer Res. 2007 Mar 1;67(5):1898-901
pubmed: 17332315
Ann Intern Med. 2016 Oct 18;165(8):607-608
pubmed: 27750310
J Clin Oncol. 2009 Feb 20;27(6):897-903
pubmed: 19139435
J Clin Oncol. 2011 Aug 1;29(22):3065-71
pubmed: 21709186
Curr Treat Options Oncol. 2015 Jul;16(7):34
pubmed: 26076798
Pediatr Dev Pathol. 2001 Mar-Apr;4(2):129-37
pubmed: 11178628
Blood. 2014 Sep 4;124(10):1570-7
pubmed: 25006130
J Clin Oncol. 2009 Oct 20;27(30):5056-61
pubmed: 19738127
Blood. 2003 Aug 15;102(4):1458-65
pubmed: 12714494
Cancer Res. 1995 Nov 15;55(22):5335-41
pubmed: 7585597
Biol Blood Marrow Transplant. 2010 Feb;16(2):223-30
pubmed: 19800015
Blood. 2017 Dec 21;130(25):2709-2717
pubmed: 28974506
J Clin Oncol. 2020 Dec 1;38(34):3999-4009
pubmed: 32730187
Ann Oncol. 2014 Nov;25(11):2211-2217
pubmed: 25193992
Blood. 2007 Dec 15;110(13):4370-2
pubmed: 17909075
J Clin Oncol. 2005 Jan 20;23(3):541-7
pubmed: 15659500
Blood. 1999 Apr 15;93(8):2697-706
pubmed: 10194450
Pediatr Blood Cancer. 2014 Dec;61(12):2236-42
pubmed: 25156886
Leukemia. 2013 Feb;27(2):416-22
pubmed: 22907048
PLoS One. 2016 Aug 12;11(8):e0160890
pubmed: 27518442
Br J Haematol. 2006 Apr;133(2):176-82
pubmed: 16611309
Cancer. 2002 Mar 15;94(6):1830-5
pubmed: 11920547
Lancet Haematol. 2018 Oct;5(10):e450-e461
pubmed: 30290902
Lancet. 2017 Aug 5;390(10094):555-566
pubmed: 28600132
Int J Cancer. 1982 Oct 15;30(4):445-59
pubmed: 6754630
Clin Cancer Res. 2010 Feb 1;16(3):888-97
pubmed: 20086002
J Clin Oncol. 2014 Oct 1;32(28):3137-43
pubmed: 25135998
Am J Pathol. 1988 Jan;130(1):59-70
pubmed: 2827494
Blood. 2016 May 19;127(20):2375-90
pubmed: 26980727
J Clin Oncol. 2010 Sep 1;28(25):3987-93
pubmed: 20679620
Lancet. 2019 Jan 19;393(10168):229-240
pubmed: 30522922
Br J Haematol. 2010 Oct;151(2):159-66
pubmed: 20738307
Pediatr Blood Cancer. 2009 Mar;52(3):335-9
pubmed: 18985718
Cancer Res. 2002 Jul 1;62(13):3736-42
pubmed: 12097283
ISRN Hematol. 2011;2011:623924
pubmed: 22084700
Blood. 2015 Feb 26;125(9):1394-402
pubmed: 25573987
Blood. 2021 Jul 1;137(26):3595-3603
pubmed: 33684925
J Clin Oncol. 2015 Nov 10;33(32):3759-65
pubmed: 26261247
Blood. 1985 Oct;66(4):848-58
pubmed: 3876124
Ann Oncol. 2022 Mar;33(3):288-298
pubmed: 34921960
J Clin Oncol. 2012 Jun 20;30(18):2183-9
pubmed: 22454421
Ann Hematol. 2016 Oct;95(11):1913-5
pubmed: 27473193
Blood. 1989 Oct;74(5):1678-89
pubmed: 2477085
Clin Cancer Res. 2012 Jan 1;18(1):248-55
pubmed: 22080439
Pediatr Blood Cancer. 2018 Apr;65(4):
pubmed: 29193772
Cancer Immunol Res. 2014 Aug;2(8):741-55
pubmed: 24916470
J Hematol Oncol. 2014 Mar 19;7:24
pubmed: 24642247
J Clin Oncol. 2013 Jun 1;31(16):1970-6
pubmed: 23610113